Sexually Transmitted Infections Overview

Sexually transmitted infections (STIs) represent a critical area of clinical medicine, demanding a nuanced understanding of presentation, diagnosis, and management. For the pre-medical and medical student, mastering these pathogens is essential not only for board examinations but for future patient care. A systematic, high-yield exploration of the most common bacterial and viral STIs focuses on their distinctive clinical fingerprints and the imperative for comprehensive screening.

Bacterial STIs: Chlamydia and Gonorrhea

Chlamydia trachomatis is the most common reportable bacterial STI in many countries. Its clinical significance is magnified by its often asymptomatic nature, particularly in women. When symptoms do occur, they typically manifest as urethritis in men (dysuria, urethral discharge) and cervicitis in women (intermenstrual bleeding, mucopurulent discharge). The insidious nature of this infection lies in its complications: untreated, it can ascend to cause pelvic inflammatory disease (PID), leading to chronic pelvic pain, ectopic pregnancy, and infertility. Diagnosis is primarily via nucleic acid amplification tests (NAATs) on urine or swab samples. Treatment involves antibiotics like azithromycin or doxycycline, with a critical emphasis on treating sexual partners to prevent reinfection.

Gonorrhea, caused by Neisseria gonorrhoeae, frequently presents with more overt symptoms. In males, it typically causes acute, purulent urethritis. In females, it can cause cervicitis, but again may be asymptomatic. A key clinical concern is its potential for disseminated gonococcal infection (DGI), where the bacterium spreads through the bloodstream, causing petechial or pustular skin lesions, asymmetric arthralgia, tenosynovitis, and, rarely, endocarditis or meningitis. Gonorrhea and chlamydia coinfection is common, so empirical treatment for both is standard. The rise of antibiotic-resistant strains makes culture and sensitivity testing increasingly important, with dual therapy (ceftriaxone plus azithromycin) often recommended.

Syphilis: The Great Imitator

Syphilis, caused by the spirochete Treponema pallidum, is notorious for its multi-stage progression, each with distinct clinical presentations. The primary stage is marked by a single, painless chancre at the site of inoculation (e.g., genitals, anus, mouth), which heals spontaneously within 3-6 weeks. The secondary stage follows, characterized by systemic manifestations including a non-pruritic rash (often on palms and soles), condylomata lata (moist papules), mucocutaneous lesions, and flu-like symptoms.

After secondary symptoms resolve, the infection enters the latent stage, which is subdivided into early latent (<1 year) and late latent (>1 year), with no visible signs but positive serology. Without treatment, up to a third of patients may progress to tertiary syphilis years to decades later, affecting the cardiovascular system (aortic aneurysms), nervous system (neurosyphilis with tapes dorsalis or general paresis), or forming gummatous lesions in various organs. Diagnosis relies on a two-step serologic process: a non-treponemal test (RPR or VDRL) for screening and a treponemal test (FTA-ABS or TP-PA) for confirmation. Penicillin G remains the definitive treatment at all stages.

Viral STIs: Herpes Simplex Virus and Human Papillomavirus

Herpes Simplex Virus Type 2 (HSV-2) is the primary cause of recurrent genital herpes, though HSV-1 is an increasingly common cause. The classic presentation involves painful, grouped vesicles on an erythematous base that ulcerate, crust, and heal over 2-4 weeks. The initial outbreak is often the most severe, potentially associated with fever, malaise, and lymphadenopathy. A key hallmark is viral latency in sacral dorsal root ganglia, leading to recurrent symptomatic episodes or asymptomatic viral shedding, which facilitates transmission. Diagnosis can be confirmed via viral PCR from a lesion swab or type-specific serology. While antiviral medications (acyclovir, valacyclovir) do not eradicate the virus, they effectively reduce symptom duration, severity, and transmission risk.

Human Papillomavirus (HPV) encompasses over 100 strains, with a spectrum from benign to oncogenic. Low-risk types (e.g., 6 and 11) cause condylomata acuminata (genital warts), which are flesh-colored, exophytic growths. High-risk oncogenic types (e.g., 16 and 18) are the etiological agents for nearly all cases of cervical cancer, as well as other anogenital and oropharyngeal cancers. The infection is often cleared by the immune system, but persistent infection with high-risk strains drives carcinogenesis. Prevention has been revolutionized by the HPV vaccine. Cervical cancer screening via Pap smears (cytology) and/or HPV DNA testing is a cornerstone of secondary prevention, allowing for the detection and treatment of precancerous lesions.

Clinical Approach: Coinfection and Screening Principles

A fundamental tenet of STI management is the high frequency of coinfection. A patient presenting with one STI has a significantly elevated risk of harboring others. For example, a patient with gonorrhea has a high concurrent probability of chlamydia. Therefore, comprehensive screening is not just recommended but is a standard of care. For any patient diagnosed with an STI, testing for HIV, syphilis, and hepatitis B and C should be strongly considered, in addition to testing for the other common bacterial and viral pathogens discussed.

This principle extends to the patient history and physical exam. A clinical encounter for a possible STI should be guided by a non-judgmental, thorough sexual history and a systematic examination. Asymptomatic screening guidelines exist for sexually active young women (chlamydia/gonorrhea), men who have sex with men (HIV, syphilis, chlamydia, gonorrhea, hepatitis), and others based on risk factors. This proactive approach is crucial for interrupting transmission chains and preventing long-term sequelae.

Common Pitfalls

1. Missing Asymptomatic Infections: Relying solely on symptomatic presentation is a critical error. Always inquire about testing history and risk factors, and follow evidence-based screening guidelines, especially for chlamydia in young women.
2. Inadequate Partner Management: Treating the index patient without ensuring partner treatment (via patient-delivered partner therapy or formal referral) guarantees reinfection and perpetuates community spread. This is a key point of patient counseling.
3. Misstaging Syphilis: Confusing the rash of secondary syphilis with a drug reaction or other dermatosis can lead to a missed diagnosis. Always consider syphilis in the differential for a diffuse, non-pruritic rash, especially involving palms and soles. Rely on staged treatment protocols based on careful clinical and serologic assessment.
4. Neglecting the Cancer Link with HPV: Dismissing HPV as "just warts" overlooks its oncogenic potential. Ensure patients understand the importance of routine cervical cancer screening (Pap/HPV tests) regardless of vaccination status, as the vaccine does not protect against all high-risk strains.

Summary

• Chlamydia trachomatis is the most common bacterial STI and is frequently asymptomatic, making routine screening vital to prevent ascending infection and infertility.
• Gonorrhea often presents with purulent discharge and carries a risk of disseminated infection; empirical dual therapy covering both gonorrhea and chlamydia is standard due to frequent coinfection.
• Syphilis progresses through distinct primary, secondary, latent, and tertiary stages, earning its reputation as "the great imitator," and requires staged treatment with penicillin.
• HSV-2 causes recurrent, painful genital ulcerations and establishes lifelong latency, with management focused on antiviral suppression rather than cure.
• HPV has low-risk strains that cause genital warts and high-risk oncogenic strains that are the primary cause of cervical cancer, prevented through vaccination and regular screening.
• Coinfection is common; the diagnosis of one STI should automatically prompt testing for other major sexually transmitted pathogens, including HIV and syphilis.